Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China.

Xiong ChaogangAn MengnaWang ZhenLi YingGu XinZhang XinZhang ShengjieZhao YuanLei QianMa WenbinFeng Weiyi

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2024)

Mepolizumab is not a cost-effective healthcare resource in China at its current pricing.

Keyphrases